Overview
Dr. James Davis is a practicing physician of Internal Medicine, and serves as the Medical Director for Duke Center for Smoking Cessation, Director of the Duke Smoking Cessation Program and Co-Director of the Duke-UNC Tobacco Treatment Specialist Credentialing Program. His research focuses on development of new pharmaceutical treatments for smoking cessation. He is principal investigator on several trials including a study on “adaptive” smoking cessation and several trials on new medications for smoking cessation. The new medications leverage more novel neurobiological mechanisms - NMDA receptor antagonism, nicotinic receptor antagonism, which impact addiction-based learning and cue response. Additionally, Dr. Davis serves as co-investigator on trials on lung cancer screening, e-cigarettes, minor nicotine alkaloids, imaging trials, lung function trials and others. Dr. Davis leads the Duke Smoke-Free Policy Initiative, is co-author on a national tobacco dependence treatment guideline, and provides training in tobacco dependence treatment for the Duke School of Medicine, Duke Internal Medicine, Family Practice and Psychiatry residency programs.
Current Appointments & Affiliations
Associate Professor of Medicine
·
2024 - Present
Medicine, General Internal Medicine,
Medicine
Member of the Duke Cancer Institute
·
2013 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Longitudinal Assessment of Communication With Patient-Reported Outcomes During Lung Cancer Screening.
Journal Article Chest · March 2025 BACKGROUND: Many organizations recommend clinicians use structured communication processes, referred to as shared decision-making, to improve patient-reported outcomes for patients considering lung cancer screening (LCS). RESEARCH QUESTION: Which component ... Full text Link to item CiteAssociations of Concordant and Shared Lung Cancer Screening Decision Making with Decisional Conflict: A Multi-Institution Cross-Sectional Analysis
Journal Article MDM Policy and Practice · January 1, 2025 Introduction. Many organizations recommend structured communication processes, including formal shared decision making (SDM), for patients undergoing lung cancer screening (LCS) using low-dose computed tomography (LDCT). We sought to understand if concorda ... Full text CiteUse of low-dose varenicline in patients who do not tolerate standard-dose varenicline: A longitudinal case series
Journal Article Tobacco Prevention and Cessation · January 1, 2025 INTRODUCTION Although varenicline tartrate is the most effective monotherapy for smoking cessation, the standard-dose (1 mg twice daily) is associated with adverse events: gastrointestinal, sleep-related, and mood-related. Lower doses have demonstrated sim ... Full text CiteRecent Grants
DELFI - Investigating the Clinical Utility of DELFI L301 Evaluation of Lung Cancer Screening
Clinical TrialPrincipal Investigator · Awarded by Delfi Diagnostics, Inc. · 2023 - 2028CASCADE - Lung
Clinical TrialPrincipal Investigator · Awarded by Delfi Diagnostics, Inc. · 2022 - 2027Comprehensive Research Program Development and Aerosol Acceptability PIL & Technology Comprehension Study
Clinical TrialPrincipal Investigator · Awarded by Predictably Human, Inc · 2021 - 2026View All Grants
External Links
CV James Davis 2019 Video - Duke Smoking Cessation Program Duke Smoking Cessation Program Smoking Cessation Interventions Duke Center for Smoking Cessation Duke-UNC Tobacco Treatment Specialist Training Program Duke Faculty Spotlight Duke Medicine Profile Duke Cancer Institute Profile